Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
AssigneePathological LLC
InventorsJohn MCKEARN, Jeremy BLITZER
Life of this patent
Estimating the term…
Abstract
Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
Claims32
An oral pharmaceutical composition, comprising MGBG together with at least one oral pharmaceutically acceptable excipient, which yields a therapeutically effective systemic plasma MGBG level when orally administered to a subject.
(canceled)
(canceled)
A low-dose oral pharmaceutical composition for chronic delivery, comprising a therapeutically effective amount of MGBG and at least one pharmaceutically acceptable excipient, which does not have substantial gastrointestinal side effects.
(canceled)
25-30. (canceled)
A method of treating or delaying the onset or development of a condition chosen from a proliferative disorder, an inflammatory disease, and an autoimmune disease, and neuropathy, comprising administering to a subject in need thereof a therapeutically effective amount of an oral pharmaceutical composition comprising MGBG and at least one pharmaceutically acceptable excipient.
34-39. (canceled)
42-52. (canceled)
Dependencies are inferred from the claim text.